|
k
|
n
|
SMD (95% CIs)
|
p
|
I2 (%)
|
---|
Overall
|
81
|
956
|
0.15 [0.12, 0.18]
|
<0.001
|
6.4
|
Design
| | |
Qb: 2.37
|
0.121
| |
Crossover
|
76
|
856
|
0.14 [0.11, 0.17]
|
<0.001
|
0
|
Parallel
|
5
|
100
|
0.36 [0.08, 0.64]
|
0.011
|
32
|
Blinding
| | |
Qb: 1.29
|
0.544
| |
Single blind
|
8
|
77
|
0.11 [-0.002, 0.22]
|
0.054
|
0
|
Double blind
|
71
|
857
|
0.16 [0.12, 0.19]
|
<0.001
|
0
|
Unclear
|
2
|
22
|
0.07 [-0.14, 0.29]
|
0.519
|
60
|
Supplementation duration
| | |
Qb: 3.05
|
0.084
| |
Acute
|
38
|
437
|
0.12 [0.06, 0.17]
|
<0.001
|
13
|
Multiple days
|
43
|
519
|
0.18 [0.13, 0.22]
|
<0.001
|
9
|
Sex1
| | |
Qb: 6.94
|
0.031
| |
Male
|
59
|
658
|
0.16 [0.12, 0.20]
|
<0.001
|
0
|
Female
|
4
|
48
|
0.0 [-0.12, 0.11]
|
0.988
|
0
|
Mixed
|
16
|
229
|
0.15 [0.09, 0.21]
|
<0.001
|
0
|
Performance level
| | |
Qb: 8.78
|
0.032
| |
PL12
|
1
|
14
|
-0.29 [-0.69, 0.11]
|
0.156
|
-
|
PL2
|
23
|
290
|
0.24 [0.12, 0.35]
|
<0.001
|
52
|
PL2 females
|
-
| | | | |
PL2 males:
|
17
|
181
|
0.24 [0.11, 0.36]
|
<0.001
|
52
|
GXT
|
3
|
34
|
0.16 [-0.14, 0.46]
|
0.300
|
80
|
IGXT
|
1
|
14
|
0.22 [0.01, 0.44]
|
0.040
| |
ITTE
|
1
|
12
|
0.47 [0.03, 0.91]
|
0.038
| |
TT
|
4
|
47
|
0.01 [-0.28, 0.29]
|
0.975
|
53
|
TTE
|
8
|
74
|
0.39 [0.21, 0.57]
|
<0.001
|
27
|
PL3
|
15
|
154
|
0.18 [0.12, 0.24]
|
<0.001
|
0
|
PL3 females
|
-
| | | | |
PL3 males:
|
15
|
154
|
0.18 [0.12, 0.24]
|
<0.001
|
0
|
GXT
|
2
|
17
|
0.1 [-0.27, 0.47]
|
0.612
|
53
|
ITT
|
2
|
20
|
0.17 [0, 0.35]
|
0.592
|
0
|
TT
|
8
|
82
|
0.17 [0.1, 0.24]
|
<0.001
|
0
|
TTE
|
3
|
35
|
0.26 [-0.18, 0.69]
|
0.249
|
71
|
PL4
|
8
|
87
|
0.03 [-0.14, 0.2]
|
0.762
|
0
|
PL4 females
|
1
|
14
|
0.02 [-0.37, 0.42]
|
0.912
|
-
|
PL4 males:
|
7
|
73
|
0.03 [-0.16, 0.22]
|
0.787
|
0
|
GXT
|
1
|
12
|
2.17 [-1.8, 6.14]
|
0.289
|
-
|
TT
|
6
|
61
|
0.02 [-0.17, 0.22]
|
0.825
|
0
|
PL5
|
6
|
57
|
-0.02 [-0.22, 0.17]
|
0.821
|
0
|
PL5 females
|
1
|
12
|
-0.01 [-0.43, 0.42]
|
0.980
|
-
|
PL5 males:
|
5
|
45
|
-0.03 [-0.25, 0.19]
|
0.808
|
0
|
ITTE
|
1
|
9
|
-0.07 [-0.56, 0.42]
|
0.801
|
-
|
TT
|
4
|
36
|
-0.02 [-0.27, 0.23]
|
0.882
|
0
|
Exercise mode
| | |
Qb: 2.29
|
0.825
| |
Cycling
|
53
|
625
|
0.17 [0.12, 0.22]
|
<0.001
|
22
|
Hand cycling
|
4
|
39
|
0.02 [-0.21, 0.26]
|
0.859
|
0
|
Incline walk/run
|
1
|
14
|
-0.29 [-0.69, 0.11]
|
0.156
|
-
|
Kayaking
|
2
|
14
|
0.13 [-0.02, 0.28]
|
0.093
|
0
|
Rowing
|
2
|
20
|
0.09 [-0.24, 0.42]
|
0.604
|
0
|
Running
|
15
|
196
|
0.14 [0.07, 0.21]
|
<0.001
|
19
|
Swimming
|
4
|
48
|
0.12 [0.004, 0.23]
|
0.042
|
0
|
Test type
| | |
Qb: 10.29
|
0.059
| |
GXT
|
15
|
176
|
0.15 [0.02, 0.27]
|
0.023
|
59
|
IGXT
|
2
|
50
|
0.13 [0.03, 0.22]
|
0.008
|
0
|
ITT
|
4
|
44
|
0.13 [0.002, 0.27]
|
0.046
|
0
|
ITTE
|
2
|
21
|
0.21 [-0.02, 0.39]
|
0.244
|
60
|
TT
|
39
|
436
|
0.12 [0.07, 0.16]
|
<0.001
|
0
|
TTE
|
19
|
229
|
0.31 [0.20, 0.42]
|
<0.001
|
29
|
Test duration
| | |
Qb: 2.89
|
0.577
| |
<5 mins:
|
11
|
104
|
0.16 [0.08, 0.23]
|
<0.001
|
0
|
TT
|
8
|
70
|
0.12 [0.04, 0.21]
|
0.005
|
0
|
TTE
|
3
|
34
|
0.32 [0.07, 0.56]
|
0.011
|
29
|
5-10 mins:
|
24
|
276
|
0.18 [0.09, 0.27]
|
<0.001
|
31
|
TT
|
11
|
112
|
0.12 [0.02, 0.22]
|
0.016
|
7
|
TTE
|
13
|
164
|
0.29 [0.13, 0.44]
|
<0.001
|
40
|
10-30 mins:
|
12
|
122
|
0.16 [0.04, 0.28]
|
0.007
|
41
|
TT
|
9
|
91
|
0.12 [-0.004, 0.23]
|
0.058
|
41
|
TTE
|
3
|
31
|
0.44 [0.16, 0.73]
|
0.002
|
0
|
30-60 mins:
|
5
|
60
|
0.08 [-0.11, 0.28]
|
0.397
|
0
|
TT
|
5
|
60
|
0.08 [-0.11, 0.28]
|
0.397
|
0
|
>60 mins:
|
4
|
51
|
0.00 [-0.21, 0.21]
|
0.986
|
0
|
TT
|
4
|
51
|
0.00 [-0.21, 0.21]
|
0.986
|
0
|
Overall (TT & TTE)
|
56
|
613
|
0.15 [0.11, 0.19]
|
<0.001
|
2
|
- 1 Sex not specified in two trials. Abbreviations – GXT, graded exercise test; IGXT, intermittent graded exercise test; ITT, intermittent time-trial; ITTE, intermittent time to exhaustion; k, number of trials; LCI, lower confidence interval; n, pooled sample size; PL, performance level; Qb, between-group Q-statistic; SMD, standardised mean difference (Hedge’s g); TT, time-trial; TTE, time to exhaustion; UCI, upper confidence interval